Stockreport

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results [Yahoo! Finance]

IO Biotech, Inc.  (IOBT) 
PDF patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee Pr [Read more]